341 related articles for article (PubMed ID: 17553743)
1. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.
Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Saletu B; Trenkwalder C; Sommerville KW; Schollmayer E; Kohnen R; Stiasny-Kolster K;
Sleep Med; 2008 Mar; 9(3):228-39. PubMed ID: 17553743
[TBL] [Abstract][Full Text] [Related]
2. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Trenkwalder C; Tacken I; Schollmayer E; Kohnen R; Stiasny-Kolster K;
Sleep Med; 2008 Dec; 9(8):865-73. PubMed ID: 18753003
[TBL] [Abstract][Full Text] [Related]
3. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study.
Stiasny-Kolster K; Kohnen R; Schollmayer E; Möller JC; Oertel WH;
Mov Disord; 2004 Dec; 19(12):1432-8. PubMed ID: 15390055
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
Oertel W; Trenkwalder C; Beneš H; Ferini-Strambi L; Högl B; Poewe W; Stiasny-Kolster K; Fichtner A; Schollmayer E; Kohnen R; García-Borreguero D;
Lancet Neurol; 2011 Aug; 10(8):710-20. PubMed ID: 21705273
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study.
Inoue Y; Shimizu T; Hirata K; Uchimura N; Ishigooka J; Oka Y; Ikeda J; Tomida T; Hattori N;
Sleep Med; 2013 Nov; 14(11):1085-91. PubMed ID: 24055212
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.
Trenkwalder C; Benes H; Poewe W; Oertel WH; Garcia-Borreguero D; de Weerd AW; Ferini-Strambi L; Montagna P; Odin P; Stiasny-Kolster K; Högl B; Chaudhuri KR; Partinen M; Schollmayer E; Kohnen R;
Lancet Neurol; 2008 Jul; 7(7):595-604. PubMed ID: 18515185
[TBL] [Abstract][Full Text] [Related]
7. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch.
Högl B; Oertel WH; Stiasny-Kolster K; Geisler P; Beneš H; García-Borreguero D; Trenkwalder C; Poewe W; Schollmayer E; Kohnen R
BMC Neurol; 2010 Sep; 10():86. PubMed ID: 20920156
[TBL] [Abstract][Full Text] [Related]
8. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
Bogan RK
Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
[TBL] [Abstract][Full Text] [Related]
9. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial.
Dauvilliers Y; Benes H; Partinen M; Rauta V; Rifkin D; Dohin E; Goldammer N; Schollmayer E; Schröder H; Winkelman JW
Am J Kidney Dis; 2016 Sep; 68(3):434-43. PubMed ID: 26851201
[TBL] [Abstract][Full Text] [Related]
10. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study.
Oertel WH; Benes H; Garcia-Borreguero D; Högl B; Poewe W; Montagna P; Ferini-Strambi L; Sixel-Döring F; Trenkwalder C; Partinen M; Saletu B; Polo O; Fichtner A; Schollmayer E; Kohnen R; Cassel W; Penzel T; Stiasny-Kolster K
Sleep Med; 2010 Oct; 11(9):848-56. PubMed ID: 20813583
[TBL] [Abstract][Full Text] [Related]
11. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States.
Hening WA; Allen RP; Ondo WG; Walters AS; Winkelman JW; Becker P; Bogan R; Fry JM; Kudrow DB; Lesh KW; Fichtner A; Schollmayer E;
Mov Disord; 2010 Aug; 25(11):1675-83. PubMed ID: 20629075
[TBL] [Abstract][Full Text] [Related]
12. Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study.
Garcia-Borreguero D; Allen R; Hudson J; Dohin E; Grieger F; Moran K; Schollmayer E; Smit R; Winkelman J
Curr Med Res Opin; 2016; 32(1):77-85. PubMed ID: 26569149
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years.
Dohin E; Högl B; Ferini-Strambi L; Schollmayer E; Fichtner A; Bauer L; García-Borreguero D
Expert Opin Pharmacother; 2013 Jan; 14(1):15-25. PubMed ID: 23256574
[TBL] [Abstract][Full Text] [Related]
14. Rotigotine transdermal delivery for the treatment of restless legs syndrome.
Sixel-Döring F; Trenkwalder C
Expert Opin Pharmacother; 2010 Mar; 11(4):649-56. PubMed ID: 20163275
[TBL] [Abstract][Full Text] [Related]
15. Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome.
Garnock-Jones KP
Drugs; 2016 Jul; 76(10):1031-40. PubMed ID: 27324269
[TBL] [Abstract][Full Text] [Related]
16. Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT.
Bauer A; Cassel W; Benes H; Kesper K; Rye D; Sica D; Winkelman JW; Bauer L; Grieger F; Joeres L; Moran K; Schollmayer E; Whitesides J; Carney HC; Walters AS; Oertel W; Trenkwalder C;
Neurology; 2016 May; 86(19):1785-93. PubMed ID: 27164714
[TBL] [Abstract][Full Text] [Related]
17. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.
Trenkwalder C; Canelo M; Lang M; Schroeder H; Kelling D; Berkels R; Schollmayer E; Heidbrede T; Benes H
Sleep Med; 2017 Feb; 30():257-265. PubMed ID: 26896370
[TBL] [Abstract][Full Text] [Related]
18. Post Hoc Analysis of Data from Two Clinical Trials Evaluating the Minimal Clinically Important Change in International Restless Legs Syndrome Sum Score in Patients with Restless Legs Syndrome (Willis-Ekbom Disease).
Ondo WG; Grieger F; Moran K; Kohnen R; Roth T
J Clin Sleep Med; 2016 Jan; 12(1):63-70. PubMed ID: 26446245
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease).
Elshoff JP; Hudson J; Picchietti DL; Ridel K; Walters AS; Doggett K; Moran K; Oortgiesen M; Ramirez F; Schollmayer E
Sleep Med; 2017 Apr; 32():48-55. PubMed ID: 28366342
[TBL] [Abstract][Full Text] [Related]
20. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
Boroojerdi B; Wolff HM; Braun M; Scheller DK
Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
